Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
XALKORI (CRIZOTINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
XALKORI
NDA
Get alerts
CRIZOTINIB | N217581 | PF PRISM CV
3 strengths
3 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
3 unique patents by expiration date
All strengths
20MG
50MG
150MG
Expiring < 1yr (1)
Active (2)
Today
2027
2028
2029
2030
Today
7825137
May. 12, 2027
7858643
Oct. 8, 2029
8217057
Nov. 6, 2029
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 20MG
RLD
3 patents
0 exclusivities
▴
CAPSULE, PELLETS;ORAL | Approved: Sep 7, 2023
Patents (3)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7825137
May 12, 2027
—
—
—
U-3057
TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
—
7858643
Oct 8, 2029
—
Yes
Yes
—
—
8217057
Nov 6, 2029
—
Yes
—
—
—
#002 — 50MG
RLD
3 patents
0 exclusivities
▾
CAPSULE, PELLETS;ORAL | Approved: Sep 7, 2023
#003 — 150MG
RLD
3 patents
0 exclusivities
▾
CAPSULE, PELLETS;ORAL | Approved: Sep 7, 2023